JP2025004013A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025004013A5 JP2025004013A5 JP2024160401A JP2024160401A JP2025004013A5 JP 2025004013 A5 JP2025004013 A5 JP 2025004013A5 JP 2024160401 A JP2024160401 A JP 2024160401A JP 2024160401 A JP2024160401 A JP 2024160401A JP 2025004013 A5 JP2025004013 A5 JP 2025004013A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 101
- 239000012634 fragment Substances 0.000 claims 43
- 239000000427 antigen Substances 0.000 claims 42
- 102000036639 antigens Human genes 0.000 claims 42
- 108091007433 antigens Proteins 0.000 claims 42
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 claims 1
- 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163150373P | 2021-02-17 | 2021-02-17 | |
| US63/150,373 | 2021-02-17 | ||
| JP2023549602A JP7559257B2 (ja) | 2021-02-17 | 2022-02-16 | 抗ｃｄ３０ｌ抗体およびその使用 |
| PCT/US2022/016565 WO2022177963A1 (en) | 2021-02-17 | 2022-02-16 | Anti-cd30l antibodies and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023549602A Division JP7559257B2 (ja) | 2021-02-17 | 2022-02-16 | 抗ｃｄ３０ｌ抗体およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025004013A JP2025004013A (ja) | 2025-01-14 |
| JP2025004013A5 true JP2025004013A5 (enExample) | 2025-02-21 |
Family
ID=82931610
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023549602A Active JP7559257B2 (ja) | 2021-02-17 | 2022-02-16 | 抗ｃｄ３０ｌ抗体およびその使用 |
| JP2024160401A Pending JP2025004013A (ja) | 2021-02-17 | 2024-09-17 | 抗ｃｄ３０ｌ抗体およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023549602A Active JP7559257B2 (ja) | 2021-02-17 | 2022-02-16 | 抗ｃｄ３０ｌ抗体およびその使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20240254246A1 (enExample) |
| EP (1) | EP4294840A4 (enExample) |
| JP (2) | JP7559257B2 (enExample) |
| KR (1) | KR20230157356A (enExample) |
| CN (2) | CN118047872A (enExample) |
| AR (1) | AR124895A1 (enExample) |
| AU (1) | AU2022224561A1 (enExample) |
| BR (1) | BR112023016445A2 (enExample) |
| CA (1) | CA3208060A1 (enExample) |
| CL (1) | CL2023002393A1 (enExample) |
| CO (1) | CO2023011962A2 (enExample) |
| CR (1) | CR20230445A (enExample) |
| EC (1) | ECSP23070234A (enExample) |
| GE (3) | GEAP202516710A (enExample) |
| IL (1) | IL305146A (enExample) |
| MX (1) | MX2023009621A (enExample) |
| PE (1) | PE20231680A1 (enExample) |
| TW (1) | TW202302637A (enExample) |
| WO (1) | WO2022177963A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021133822A1 (en) | 2019-12-24 | 2021-07-01 | Juvena Therapeutics,Inc. | Regenerative polypeptides and uses thereof |
| CN118047872A (zh) * | 2021-02-17 | 2024-05-17 | 普罗米修斯生物科学公司 | 抗cd30l抗体和其用途 |
| CA3223707A1 (en) | 2021-06-21 | 2022-12-29 | Hanadie Yousef | Regenerative polypeptides and uses thereof |
| TW202417045A (zh) * | 2022-07-25 | 2024-05-01 | 美商普羅米修斯生物科學股份有限公司 | 抗cd30l抗體、其調配物及其用途 |
| WO2024143497A1 (ja) * | 2022-12-28 | 2024-07-04 | 国立大学法人京都大学 | Ｃｄ１５３を標的とする医薬組成物 |
| AR133766A1 (es) * | 2023-09-12 | 2025-10-29 | Amgen Inc | Anticuerpos anti-cd30l y usos de los mismos |
| WO2025075049A1 (ja) * | 2023-10-03 | 2025-04-10 | 国立大学法人京都大学 | ヒトｃｄ１５３を標的とする抗体ならびにキメラ抗原受容体 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| DK0615451T3 (da) * | 1992-05-26 | 2006-04-24 | Immunex Corp | Hidtil ukendt cytokin der binder til CD30 |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PT1068241E (pt) | 1998-04-02 | 2007-11-19 | Genentech Inc | Variantes de anticorpos e respectivos fragmentos |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6652854B2 (en) * | 2000-08-08 | 2003-11-25 | Immunex Corporation | Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US20080233119A2 (en) | 2003-08-20 | 2008-09-25 | University Of Miami | Compositions and methods for treating inflammatory lung disease |
| AU2012325798B2 (en) * | 2011-10-21 | 2015-11-26 | Société des Produits Nestlé S.A. | Methods for improving inflammatory bowel disease diagnosis |
| KR101932697B1 (ko) * | 2012-04-27 | 2019-03-21 | 노보 노르디스크 에이/에스 | 사람 cd30 리간드 항원 결합 단백질 |
| CA2997444A1 (en) * | 2015-09-29 | 2017-04-06 | Amgen Inc. | Asgr inhibitors for reducing cholesterol levels |
| US20210208162A1 (en) | 2016-01-19 | 2021-07-08 | Global Down Syndrome Foundation | Down syndrome biomarkers and uses thereof |
| MA52251A (fr) * | 2018-04-30 | 2021-02-17 | Cedars Sinai Medical Center | Procédés et systèmes de sélection et de traitement de patients souffrant de maladies inflammatoires |
| WO2020096046A1 (ja) | 2018-11-09 | 2020-05-14 | 国立大学法人大阪大学 | 老化関連ｔ細胞を標的とした糖代謝異常の予防または治療用ワクチン |
| CN118047872A (zh) | 2021-02-17 | 2024-05-17 | 普罗米修斯生物科学公司 | 抗cd30l抗体和其用途 |
-
2022
- 2022-02-16 CN CN202410189800.6A patent/CN118047872A/zh active Pending
- 2022-02-16 WO PCT/US2022/016565 patent/WO2022177963A1/en not_active Ceased
- 2022-02-16 TW TW111105667A patent/TW202302637A/zh unknown
- 2022-02-16 AR ARP220100318A patent/AR124895A1/es unknown
- 2022-02-16 GE GEAP202516710A patent/GEAP202516710A/en unknown
- 2022-02-16 BR BR112023016445A patent/BR112023016445A2/pt unknown
- 2022-02-16 CA CA3208060A patent/CA3208060A1/en active Pending
- 2022-02-16 JP JP2023549602A patent/JP7559257B2/ja active Active
- 2022-02-16 GE GEAP202416351A patent/GEAP202416351A/en unknown
- 2022-02-16 CR CR20230445A patent/CR20230445A/es unknown
- 2022-02-16 MX MX2023009621A patent/MX2023009621A/es unknown
- 2022-02-16 US US18/546,955 patent/US20240254246A1/en active Pending
- 2022-02-16 EP EP22756817.7A patent/EP4294840A4/en active Pending
- 2022-02-16 AU AU2022224561A patent/AU2022224561A1/en active Pending
- 2022-02-16 KR KR1020237031681A patent/KR20230157356A/ko active Pending
- 2022-02-16 PE PE2023002377A patent/PE20231680A1/es unknown
- 2022-02-16 CN CN202280028982.8A patent/CN117255802A/zh active Pending
- 2022-02-16 GE GEAP202216351A patent/GEP20257791B/en unknown
- 2022-02-16 IL IL305146A patent/IL305146A/en unknown
- 2022-08-26 US US17/822,598 patent/US11866505B2/en active Active
-
2023
- 2023-08-14 CL CL2023002393A patent/CL2023002393A1/es unknown
- 2023-09-08 CO CONC2023/0011962A patent/CO2023011962A2/es unknown
- 2023-09-14 EC ECSENADI202370234A patent/ECSP23070234A/es unknown
- 2023-11-15 US US18/510,511 patent/US20240092923A1/en active Pending
-
2024
- 2024-09-17 JP JP2024160401A patent/JP2025004013A/ja active Pending